AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35286526 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS over left dorsolateral prefrontal cortex (DLPFC) for 20 min
Number of subjects: 32
Study 35286526 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment over left dorsolateral prefrontal cortex (DLPFC) for 20 min
Number of subjects: 32
Study 35286526 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS
Number of subjects: 32
Study 36040972 — intervention group
Group type: EXPERIMENTAL
Intervention: H7 coil
Number of subjects: 8
Study 36040972 — intervention group
Group type: COMPARATOR
Intervention: D‐B80 coil
Number of subjects: 8
Study 33947259 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal intracapsular tonsillectomy (n=87)
Number of subjects: 162
Study 33947259 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy (n=75)
Number of subjects: 162
Study 36271950 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-mg ibuprofen
Number of subjects: 20
Study 36271950 — intervention group
Group type: EXPERIMENTAL
Intervention: 600-mg ibuprofen
Number of subjects: 20
Study 36271950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 34853302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent vemurafenib (BRAFi) plus cobimetinib (MEKi)
Number of subjects: 0
Study 34853302 — intervention group
Group type: COMPARATOR
Intervention: Standard continuous vemurafenib (BRAFi) plus cobimetinib (MEKi)
Number of subjects: 0
Study 36071224 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic analyses to target therapy
Number of subjects: 0
Study 32192658 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-associated acute kidney injury (CA-AKI)
Number of subjects: 4418
Study 32192658 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 4418
Study 33215762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg
Number of subjects: 63
Study 33215762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 150 mg
Number of subjects: 63
Study 33215762 — intervention group
Group type: COMPARATOR
Intervention: Late-start nilotinib 150 mg
Number of subjects: 63
Study 33215762 — intervention group
Group type: COMPARATOR
Intervention: Nilotinib 150 mg vs 300 mg
Number of subjects: 63
Study 35106880 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 μg LSD
Number of subjects: 56
Study 35106880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 35106880 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 μg LSD
Number of subjects: 56
Study 33009186 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ventilation
Number of subjects: 60
Study 33009186 — intervention group
Group type: COMPARATOR
Intervention: Controlled ventilation (bag-mask ventilation)
Number of subjects: 60
Study 35689598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB)
Number of subjects: 106
Study 33745099 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship education and HIV prevention program for male couples
Number of subjects: 0
Study 33745099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP)
Number of subjects: 0
Study 32220245 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (WHO food safety manual)
Number of subjects: 125
Study 32220245 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 34446223 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced postoperative surveillance intervention
Number of subjects: 96
Study 34446223 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical staff enthusiasm for the trial
Number of subjects: 96
Study 34446223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing management support of the trial
Number of subjects: 96
Study 34446223 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance of a dummy run
Number of subjects: 96
Study 34446223 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing colleagues seeing the value of the intervention(s)
Number of subjects: 96
Study 34446223 — intervention group
Group type: EXPERIMENTAL
Intervention: Site investigators' belief in the effectiveness of the intervention
Number of subjects: 96
Study 32476009 — intervention group
Group type: EXPERIMENTAL
Intervention: SALAS score (5-25 points) assigned by trained reviewers based on video and voice recordings
Number of subjects: 20
Study 32476009 — intervention group
Group type: EXPERIMENTAL
Intervention: SALAS score
Number of subjects: 20
Study 33624337 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Gynaecological Cancer Support (MGCS) program for 24 weeks along with routine care
Number of subjects: 168
Study 33624337 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 168
Study 32986363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer treatment modalities (radiotherapy, brachytherapy, chemotherapy, surgery)
Number of subjects: 248
Study 32986363 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-pocket expenditure (OOPE)
Number of subjects: 248
Study 32986363 — intervention group
Group type: EXPERIMENTAL
Intervention: Catastrophic health expenditure (CHE)
Number of subjects: 248
Study 32986363 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress financing
Number of subjects: 248
Study 32986363 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with CHE
Number of subjects: 248
Study 32986363 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with distress financing
Number of subjects: 248
Study 32986363 — intervention group
Group type: EXPERIMENTAL
Intervention: Health benefit package (HBP) cost for brachytherapy and radiotherapy
Number of subjects: 248
Study 34096954 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein product
Number of subjects: 34
Study 34096954 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate (CHO) product
Number of subjects: 34
Study 34096954 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 34
Study 33971853 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-predicted nomogram for sepsis associated-acute kidney injury (SA-AKI) developed through multivariate logistic regression analysis.
Number of subjects: 2871
Study 33971853 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the nomogram in the validation cohort.
Number of subjects: 2871
Study 33971853 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis (DCA) of the nomogram.
Number of subjects: 2871
Study 32036491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg daily on days 2-4)
Number of subjects: 95
Study 32036491 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard triplet regimen comprising aprepitant, a 5-HT3 receptor antagonist, and dexamethasone 7.5 mg on days 2-4)
Number of subjects: 95
Study 32036491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 95
Study 32036491 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 34775517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 34775517 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (980 nm, 3-W)
Number of subjects: 36
Study 34775517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1064, 1.0-W)
Number of subjects: 36
Study 34775517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanobioglass
Number of subjects: 36
Study 34775517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanobioglass + diode laser (980 nm)
Number of subjects: 36
Study 34775517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanobioglass + Nd:YAG laser
Number of subjects: 36
Study 34204618 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyphenolic nutraceutical
Number of subjects: 108
Study 34204618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 33374524 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated dry maté extract providing 580 mg of caffeoyl quinic acid derivatives (CQAs) daily
Number of subjects: 34
Study 33374524 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated dry maté extract
Number of subjects: 34
Study 33374524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 33374524 — intervention group
Group type: EXPERIMENTAL
Intervention: Maté extract (subgroup analysis)
Number of subjects: 34
Study 35857574 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Postpartum Sexual Health Program (WPSHP)
Number of subjects: 80
Study 33876556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptives (CHCs)
Number of subjects: 16
Study 33876556 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormonal contraceptives)
Number of subjects: 16
Study 32740481 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/P4 1/100
Number of subjects: 726
Study 32740481 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/P4 0.5/100
Number of subjects: 726
Study 32740481 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/P4 0.5/50
Number of subjects: 726
Study 32740481 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/P4 0.25/50
Number of subjects: 726
Study 32740481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study 32740481 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/P4 (all doses)
Number of subjects: 726
Study 33852195 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle (PBO)
Number of subjects: 10
Study 33856589 — intervention group
Group type: EXPERIMENTAL
Intervention: Resective surgery with the insertion of HAM patch (Group A)
Number of subjects: 49
Study 33856589 — intervention group
Group type: COMPARATOR
Intervention: Resective surgery (Group B)
Number of subjects: 49
Study 35314922 — intervention group
Group type: EXPERIMENTAL
Intervention: New suturing technique
Number of subjects: 20
Study 35314922 — intervention group
Group type: COMPARATOR
Intervention: Routine simple interrupted stitches (Control)
Number of subjects: 20
Study 34520468 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability intervention (replacing higher energy products with lower energy products)
Number of subjects: 20327
Study 34520468 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability plus size intervention (reducing portion size of higher energy products)
Number of subjects: 20327
Study 34520468 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability plus size intervention
Number of subjects: 20327
Study 35365582 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib in the Oral Psoriatic Arthritis TriaL program
Number of subjects: 0
Study 35365582 — intervention group
Group type: EXPERIMENTAL
Intervention: ixekizumab in the SPIRIT-P1 randomized controlled trial
Number of subjects: 0
Study 32530321 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive (MI) bilateral laminotomy
Number of subjects: 62
Study 32530321 — intervention group
Group type: COMPARATOR
Intervention: Open laminectomy
Number of subjects: 62
Study 32560674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulch with nitrogen fertilizer application
Number of subjects: 4
Study 32560674 — intervention group
Group type: COMPARATOR
Intervention: No mulch with nitrogen fertilizer application
Number of subjects: 4
Study 32560674 — intervention group
Group type: EXPERIMENTAL
Intervention: High planting density with mulch and moderate N fertilizer application rate
Number of subjects: 4
Study 32560674 — intervention group
Group type: EXPERIMENTAL
Intervention: Different plant organs (leaf, grain, stem, cob)
Number of subjects: 4
Study 32560674 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaves
Number of subjects: 4
Study 32560674 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetative organ N translocation efficiency
Number of subjects: 4
Study 35891905 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise at 50 dB
Number of subjects: 66
Study 35891905 — intervention group
Group type: COMPARATOR
Intervention: 0 dB (control group)
Number of subjects: 66
Study 36116927 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant poly-epitope vaccine EgG1Y162-2 (4)
Number of subjects: 0
Study 36116927 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant multiepitope protein HIS-EgG1Y162-2 (4)
Number of subjects: 0
Study 32172239 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0
Study 32172239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35878952 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day practice group
Number of subjects: 0
Study 35878952 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day practice group
Number of subjects: 0
Study 35878952 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task condition
Number of subjects: 0
Study 35878952 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition
Number of subjects: 0
Study 35878952 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror test
Number of subjects: 0
Study 35878952 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-mirror test
Number of subjects: 0
Study 34283844 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt substitute
Number of subjects: 516
Study 34283844 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 516
Study 34283844 — intervention group
Group type: EXPERIMENTAL
Intervention: Media intervention
Number of subjects: 516
Study 32489777 — intervention group
Group type: EXPERIMENTAL
Intervention: Endeavor®-zotarolimus-eluting stent (E-ZES)
Number of subjects: 767
Study 32489777 — intervention group
Group type: COMPARATOR
Intervention: Resolute integrity®-zotarolimus-eluting stent (I-ZES)
Number of subjects: 767
Study 34156639 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet with 50 mg/kg zinc acetate (T1)
Number of subjects: 180
Study 34156639 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet with 200 mg/kg zinc acetate (T2)
Number of subjects: 180
Study 34156639 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal diet with 300 mg/kg zinc acetate (T3)
Number of subjects: 180
Study 34156639 — intervention group
Group type: COMPARATOR
Intervention: Basal diet with normal zinc level (Control)
Number of subjects: 180
Study 34807723 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine fluid administration deemed inappropriate
Number of subjects: 0
Study 34807723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-PCI interventions
Number of subjects: 0
Study 34807723 — intervention group
Group type: EXPERIMENTAL
Intervention: Right heart catheterization
Number of subjects: 0
Study 34807723 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular unloading strategies
Number of subjects: 0
Study 34807723 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of futility for mechanical circulatory support escalation
Number of subjects: 0
Study 35494511 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaha system nursing (intervention group)
Number of subjects: 62
Study 35494511 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing (control group)
Number of subjects: 62
Study 32459282 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS) supplementation (16 g/day for four weeks)
Number of subjects: 42
Study 32459282 — intervention group
Group type: COMPARATOR
Intervention: Placebo (manioc flour)
Number of subjects: 42
Study 32459282 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS) supplementation
Number of subjects: 42
Study 32459282 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements
Number of subjects: 42
Study 35711677 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based dementia caregiver intervention (CDCI)
Number of subjects: 78
Study 35711677 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 78
Study 34452904 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 555
Study 34452904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 36008082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ductal lavage
Number of subjects: 0
Study 36008082 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids (Methylprednisolone)
Number of subjects: 0
Study 33927790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus bupivacaine
Number of subjects: 60
Study 33927790 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine only
Number of subjects: 60
Study 32758282 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis tablet (450 mg, containing 100 mg polyphenol compounds), twice daily for 6 weeks
Number of subjects: 52
Study 32758282 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo, twice daily for 6 weeks
Number of subjects: 52
Study 35367091 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric aspiration after bimaxillary orthognathic surgery
Number of subjects: 83
Study 35367091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gastric aspiration)
Number of subjects: 83
Study 34487871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser-assisted photodynamic therapy (AFL-PDT)
Number of subjects: 48
Study 34487871 — intervention group
Group type: COMPARATOR
Intervention: Ablative fractional laser (AFL)
Number of subjects: 48
Study 36056729 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 15 mg
Number of subjects: 984
Study 36056729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 984
Study 33819472 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (540,000 International Units)
Number of subjects: 95
Study 33819472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 34969526 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with real-time computer navigation feedback
Number of subjects: 20
Study 34969526 — intervention group
Group type: COMPARATOR
Intervention: Simulation training without navigation feedback
Number of subjects: 20
Study 32729954 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) treatment
Number of subjects: 12
Study 32729954 — intervention group
Group type: COMPARATOR
Intervention: Adjacent untreated sites with recession at baseline
Number of subjects: 12
Study 32729954 — intervention group
Group type: EXPERIMENTAL
Intervention: All sites (including ADM-treated and untreated)
Number of subjects: 12
Study 32729954 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline KTW ≥2 mm
Number of subjects: 12
Study 34688699 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab treatment (8 infusions over 24 weeks)
Number of subjects: 51
Study 34688699 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab re-treatment
Number of subjects: 51
Study 34688699 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab treatment
Number of subjects: 51
Study 32663140 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaktor app for symptom self-management
Number of subjects: 149
Study 34315476 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance of at least four antenatal clinic visits (ANC 4+)
Number of subjects: 3007
Study 34315476 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding behavior
Number of subjects: 3007
Study 34315476 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular attendance at community meetings
Number of subjects: 3007
Study 34315476 — intervention group
Group type: EXPERIMENTAL
Intervention: ANC 4+
Number of subjects: 3007
Study 34315476 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 3007
Study 34315476 — intervention group
Group type: EXPERIMENTAL
Intervention: Redistribution of exclusive breastfeeding behavior
Number of subjects: 3007
Study 33027760 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar massage
Number of subjects: 0
Study 33656986 — intervention group
Group type: EXPERIMENTAL
Intervention: Random projection strategy for nonparametric testing
Number of subjects: 0
Study 33656986 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive testing procedure
Number of subjects: 0
Study 33656986 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper bounds for tail sums of empirical kernel eigenvalues
Number of subjects: 0
Study 33656986 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations and real data analysis
Number of subjects: 0
Study 34277982 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemic clamp (2.2-2.5 mmol/L)
Number of subjects: 27
Study 34277982 — intervention group
Group type: COMPARATOR
Intervention: Euglycaemic clamp (4.5-5.5 mmol/L)
Number of subjects: 27
Study 32158657 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider adenoidectomy
Number of subjects: 140
Study 32158657 — intervention group
Group type: COMPARATOR
Intervention: Coblation adenoidectomy
Number of subjects: 140
Study 35538139 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 59
Study 35538139 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 59
Study 32513143 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable interval risk-based screening (6, 12, or 24 months)
Number of subjects: 51
Study 32513143 — intervention group
Group type: COMPARATOR
Intervention: Annual screening
Number of subjects: 51
Study 32513143 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month interval
Number of subjects: 51
Study 32513143 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month interval
Number of subjects: 51
Study 32513143 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year interval
Number of subjects: 51
Study 35236764 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3026
Study 35236764 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 3026
Study 35236764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3026
Study 32267951 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOF Mini Well IOL
Number of subjects: 50
Study 32267951 — intervention group
Group type: COMPARATOR
Intervention: Mini‐4‐Ready IOL
Number of subjects: 50
Study 32410519 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple suction combined with pressure dressing (Group A)
Number of subjects: 84